Autopsy report · NCT00958841
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Cause of deathSlow enrollment
“Slow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment issues)”
Life of this trial
- Registered 2 months before it started.
- Ran for about 5 years 9 months before it stopped.
- 118 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
- Interventions
- pasireotide LAR
- Participants
- 118
- Sites
- 42
- Countries
- Argentina, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Russia, Spain, Thailand, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.